Advanced Micro Devices, Inc. (NASDAQ:AMD) stock has reached a 52-week low, dipping to $114.41, as investors navigate a challenging market environment. According to InvestingPro data, the company ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as ...

"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...

Absci Corp. (NASDAQ:ABSI) shares, currently trading at $3.22, received a positive outlook from Needham as the firm began coverage with a Buy rating and set a price target of $9.00. The stock has shown ...

Commerce Secretary Gina Raimondo says the US leads AI now - both AI development and AI chip design, and it’s critical that we ...

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for ...

On a separate note, AMD has announced a $20 million investment into biotech company Absci (ABSI) in a bid to deploy more of its AI accelerators and ROCM software. Advanced Micro Devices’ most recent ...

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that ...

Absci (NASDAQ:ABSI – Free Report) had its price objective cut by KeyCorp from $6.00 to $5.00 in a research note released on Wednesday,Benzinga reports.They currently have an overweight rating on ...

We recently published a list of 13 AI News and Ratings You Probably Missed. In this article, we are going to take a look at ...

Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design ...